-
Lingo Failure Leads Citi To Downgrade Biogen
Wednesday, June 8, 2016 - 10:03am | 261Read More...Biogen Inc (NASDAQ: BIIB) announced that anti-Lingo failed both the primary and the secondary endpoints in its Phase 2 RRMS trial. Citi’s Robyn Karnauskas downgraded the rating on the company from Buy to Neutral, while lowering the price target from $345 to $295. Lingo Failure “While...
-
Jefferies 'Encouraged' By Biogen Idec's New Data
Tuesday, January 20, 2015 - 1:28pm | 253Read More...In a report released Tuesday, Jefferies reiterated a Buy rating and a $410 price target (set in July) for Biogen Idec Inc (NASDAQ: BIIB). The analysts say that they feel “encouraged by the incremental color on BIIB037, suggesting the results may be more robust than we [the analysts]...
